Feasibility study with 99mTc-HYNIC-βAla-Bombesin(7-14) as an agent to early visualization of lung tumour cells in nude mice

Nuclear Medicine Communications

Volumn 37, Issue 4, 2016, Pages 372-376

  Marostica, Lucas L ^a,b   De Barros, André L B ^a   Silva, Juliana O ^a   Lopes, Sávia C A ^a   Salgado, Breno S ^a   Chondrogiannis, Sotirios ^c   Rubello, Domenico ^c   Cassali, Geovanni D ^a   Schenkel, Eloir P ^b   Cardoso, Valbert N ^a   Simões, Cláudia M O ^b   Oliveira, Mônica C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c Santa Maria Misericordia Hospital   (Italy)

Author keywords

99mTc HYNIC Ala Bombesin(7 14); A549 cell line; Lung tumour; Scintigraphic imaging; Tumour identification

Indexed keywords

BOMBESIN; TECHNETIUM 99M; ALANINE; TECHNETIUM 99M HYNIC-BETA-ALA-BOMBESIN(7-14); TECHNETIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LUNG SCINTISCANNING; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; TUMOR CELL; A-549 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; LUNG TUMOR; NUDE MOUSE; PATHOLOGY; TISSUE DISTRIBUTION;

A549 CELLS; ALANINE; ANIMALS; BOMBESIN; CELL TRANSFORMATION, NEOPLASTIC; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; ORGANOTECHNETIUM COMPOUNDS; TISSUE DISTRIBUTION;

EID: 84949035971     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000449     Document Type: Article

References (25)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: Relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31: 992-1001.
3. Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors. Methods 2009; 48: 161-177.
4. Ferro-Flores G, Ramírez Fde M, Meléndez-Alafort L, Santos-Cuevas CL. Peptides for in vivo target-specific cancer imaging. Mini Rev Med Chem 2010; 10: 87-97.
5. Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: Valuable tools for the detection and treatment of cancer. Theranostics 2012; 2: 481-501.
6. Laverman P, Sosabowski JK, Boerman OC, OyenWJ. Radiolabeled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging 2012; 39: S78-S92.
7. De Barros ALB, Mota LG, Soares DCF, Coelho MMA, Oliveira MC, Cardoso VN. Tumor bombesin analog loaded long-circulating and pH-sensitive liposomas as tool for tumor identification. Bioorg Med Chem Lett 2011; 21: 7373-7375.
8. 99mTc-labeled bombesin analog for breast cancer identification. J Radioanal Nucl Chem 2013; 295: 2083-2090.
9. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011; 38: 97-107.
10. Schroeder RPJ, van Weerden WM, Bangma C, Krenning EP, de Jong M. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 2009; 48: 200-204.
11. Kong FL, Zhang Y, Young DP, Yu DF, Yang DJ. Development of (99m)Tc-ECtyrosine for early detection of breast cancer tumor response to the anticancer drug melphalan. Acad Radiol 2013; 20: 41-51.
12. 99mTc ECDG targeted at the multifunctional glucose transport system: Feasibility study with rodents. Radiology 2003; 226: 465-473.
13. 99mTc via hydrazinonicotinamide: Description of optimized radiolabeling conditions. J Radioanal Nucl Chem 2010; 284: 539-545.
14. 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin releasing peptide receptor positive tumor cell lines. J Drug Target 2013; 21: 383-388.
15. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumorcell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976; 17: 62-70.
16. 11C]-labeled erlotinib: A micro-PET study on mice with lung tumor xenografts. Cancer Res 2009; 69: 873-878.
17. Kellar A, Egan C, Morris D. Preclinical murine models for lung cancer: Clinical trial applications. Biomed Res Int 2015; 2015: 621324.
18. Siegfried JM, Krishnamachary N, Gaither Davis A, Gubish C, Hunt JD, Shriver SP. Evidence for autocrine actions of neuromedin B and gastrinreleasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 1999; 12: 291-302.
19. de Barros AL, Mota Ld, Ferreira Cde A, Oliveira MC, Góes AM, Cardoso VN. Bombesin derivative radiolabeled with technetium-99m as agent for tumor identification. Bioorg Med Chem Lett 2010; 20: 6182-6184.
20. 99mTc-labeling of HYNIC-βAla-Bombesin[(7-14)]. Appl Radiat Isot 2012; 70: 2440-2445.
21. 99mTc-HYNIC-βAla-Bombesin(7-14) in an experimental model. J Radioanal Nucl Chem 2014; 300: 801-807.
22. Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ. Radiolabeled bombesin analogs for prostate cancer diagnosis: Preclinical studies. Nucl Med Biol 2008; 35: 401-411.
23. 99mTc-labeled bombesin(7-14) NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem 2008; 19: 1170-1178.
24. 99mTc-labeled bombesin(7-14) as an agent for pancreas tumor detection in mice. Braz J Med Biol Res 2015; 48: 923-928.
25. Phillips WT. Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev 1999; 37 (1-3): 13-32.